Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2026 08:33 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive progress in a mid-year update from the ongoing Phase 2...
June 08, 2026 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders

KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the...
June 08, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...
June 08, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Sarclisa SC approved in EU: first anticancer via on-body injector CirCLIQ®. Flexible home/clinic administration for multiple myeloma patients.
June 08, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable

Sarclisa SC approuvé en UE : 1er anticancéreux via injecteur corporel CirCLIQ®. Administration flexible domicile/clinique pour myélome multiple.
June 05, 2026 11:48 ET | Source: EnGeneIC

EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York

EnGeneIC Honored with 2026 Breakthrough in glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York
June 04, 2026 12:07 ET | Source: Allsup

Allsup Highlights Pancreatic Cancer Research And Importance Of Timely SSDI Applications

Belleville, Illinois, June 04, 2026 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work and veterans disability appeals...
June 04, 2026 10:36 ET | Source: ONCOVITA

Oncovita presents promising preclinical data on MVdeltaC, a novel onco-immunotherapy at EACR, 8-11 June 2026, in Budapest

Oncovita presents promising preclinical data on MVdeltaC, a novel onco-immunotherapy at EACR, 8-11 June 2026, in Budapest
June 04, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
June 04, 2026 03:00 ET | Source: Ona Therapeutics

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

Ona Therapeutics closes oversubscribed $86.6M Series B financing to advance first-in-class ADCs into clinical development for treatment-resistant cancers